Optimization of 89Zr PET Imaging for Improved Multisite Quantification and Lesion Detection Using an Anthropomorphic Phantom.

Our objective was to harmonize multicenter 89Zr PET imaging for oncology trials and to evaluate lesion detection. Methods: Seven PET scanners were evaluated using a custom chest oncology phantom with 9 spheric lesions 7-20 mm in diameter. A 4:1 signal-to-background ratio simulated a patient dose of 92.5 MBq. Various image reconstructions were evaluated. Images were assessed for lesion detection, and recovery coefficients and background signal variance were measured. Results: Two scanners failed to provide acceptable images and data. Optimal reconstruction algorithms enabling adequate lesion detection and reliable quantification across the other 5 scanners were determined without compromising the data quality. On average, 95% of the 10-mm lesions were detected, and the 7-mm lesion was visualized by only 1 scanner. Background variance was 8.6%-16%. Conclusion: We established multicenter harmonization procedures for 89Zr PET imaging in oncology, optimizing small-lesion (≥10 mm) detectability and accurate quantification.

Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.

The Uniform Protocols for Imaging in Clinical Trials (UPICT) (18)F-FDG PET/CT protocol is intended to guide the performance of whole-body FDG PET/CT studies within the context of single- and multiple-center clinical trials of oncologic therapies by providing acceptable (minimum), target, and ideal standards for all phases of imaging. The aim is to minimize variability in intra- and intersubject, intra- and interplatform, interexamination, and interinstitutional primary or derived data. The goal of this condensed version of the much larger document is to make readers aware of the general content and subject area. The document has several main subjects: context of the imaging protocol within the clinical trial; site selection, qualification, and training; subject scheduling; subject preparation; imaging-related substance preparation and administration; imaging procedure; image postprocessing; image analysis; image interpretation; archiving and distribution of data; quality control; and imaging-associated risks and risk management.

Quantitative PET/CT scanner performance characterization based upon the society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom.

UNLABELLED: The Clinical Trials Network (CTN) of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) operates a PET/CT phantom imaging program using the CTN's oncology clinical simulator phantom, designed to validate scanners at sites that wish to participate in oncology clinical trials. Since its inception in 2008, the CTN has collected 406 well-characterized phantom datasets from 237 scanners at 170 imaging sites covering the spectrum of commercially available PET/CT systems. The combined and collated phantom data describe a global profile of quantitative performance and variability of PET/CT data used in both clinical practice and clinical trials. METHODS: Individual sites filled and imaged the CTN oncology PET phantom according to detailed instructions. Standard clinical reconstructions were requested and submitted. The phantom itself contains uniform regions suitable for scanner calibration assessment, lung fields, and 6 hot spheric lesions with diameters ranging from 7 to 20 mm at a 4:1 contrast ratio with primary background. The CTN Phantom Imaging Core evaluated the quality of the phantom fill and imaging and measured background standardized uptake values to assess scanner calibration and maximum standardized uptake values of all 6 lesions to review quantitative performance. Scanner make-and-model-specific measurements were pooled and then subdivided by reconstruction to create scanner-specific quantitative profiles. RESULTS: Different makes and models of scanners predictably demonstrated different quantitative performance profiles including, in some cases, small calibration bias. Differences in site-specific reconstruction parameters increased the quantitative variability among similar scanners, with postreconstruction smoothing filters being the most influential parameter. Quantitative assessment of this intrascanner variability over this large collection of phantom data gives, for the first time, estimates of reconstruction variance introduced into trials from allowing trial sites to use their preferred reconstruction methodologies. Predictably, time-of-flight-enabled scanners exhibited less size-based partial-volume bias than non-time-of-flight scanners. CONCLUSION: The CTN scanner validation experience over the past 5 y has generated a rich, well-curated phantom dataset from which PET/CT make-and-model and reconstruction-dependent quantitative behaviors were characterized for the purposes of understanding and estimating scanner-based variances in clinical trials. These results should make it possible to identify and recommend make-and-model-specific reconstruction strategies to minimize measurement variability in cancer clinical trials.

Amyloid deposition and cognition in older adults: the effects of premorbid intellect.

Although amyloid deposition remains a marker of the development of Alzheimer's disease, results linking amyloid and cognition have been equivocal. Twenty-five community-dwelling non-demented older adults were examined with (18)F-flutemetamol, an amyloid imaging agent, and a cognitive battery, including an estimate of premorbid intellect and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). In the first model, (18)F-flutemetamol uptake significantly correlated with the Delayed Memory Index of the RBANS (r = -.51, p = .02) and premorbid intellect (r = .43, p = .03). In the second model, the relationship between (18)F-flutemetamol and cognition was notably stronger when controlling for premorbid intellect (e.g., three of the five RBANS Indexes and its Total score significantly correlated with (18)F-flutemetamol, r's = -.41 to -.58). Associations were found between amyloid-binding (18)F-flutemetamol and cognitive functioning in non-demented older adults. These associations were greatest with delayed memory and stronger when premorbid intellect was considered, suggesting that cognitive reserve partly compensates for the symptomatic expression of amyloid pathology in community-dwelling elderly.

(18)F-FDG PET in the evaluation of acuity of deep vein thrombosis.

PURPOSE: F-FDG PET has been used for vascular disease, but its role in deep vein thrombosis (DVT) remains prospectively unexplored. PATIENTS AND METHODS: Whole-body F-FDG PET/CT scans were performed in patients 1 to 10 weeks after onset of symptomatic DVT (n = 12) and in control subjects without DVT (n = 24). The metabolic activity (SUVmax) of thrombosed and contralateral nonthrombosed vein segments was determined. The sensitivity and specificity of F-FDG PET/CT for the diagnosis of DVT were determined by receiver operating characteristic curve analyses. In 2 patients with DVT, changes in the metabolic activity of thrombosed vein segments in serial F-FDG PET scans. RESULTS: The metabolic activity in thrombosed veins [SUVmax, 2.41 (0.75)] was visually appreciable and significantly higher than in nonthrombosed veins in either the contralateral extremity of patients with DVT [SUVmax, 1.09 (0.25), P = 0.007] or control subjects [1.21 (0.22), P < 0.001]. The area under the receiver operating characteristic curve for SUVmax was 0.9773 (P < 0.001), indicating excellent accuracy. An SUVmax threshold of greater than 1.645 was 87.5% sensitive and 100% specific for DVT. Metabolic activity in thrombosed veins correlated significantly with time from DVT symptom onset (decrease in SUVmax of 0.02/d, P < 0.05). Best-fit-line analyses suggested that approximately 84 to 91 days after acute DVT, the maximum metabolic activity of thrombosed veins would return to normal levels. CONCLUSIONS: F-FDG PET/CT is accurate for detecting acute symptomatic, proximal DVT. Metabolic activity in thrombosed veins decreases with time, suggesting that F-FDG PET may be helpful in assessing the age of the clot.

Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.

PURPOSE: The objective was to compare F-fluorodeoxyglucose (FDG) and F-fluorothymidine (FLT) PET in differentiating radiation necrosis from recurrent glioma. MATERIALS AND METHODS: Visual and quantitative analyses were derived from static FDG PET and static and dynamic FLT PET in 15 patients with suspected recurrence of treated grade 2 glioma or worse with a new focus of Gd contrast enhancement on MRI. For FDG PET, SUVmax and the ratio of lesion SUVmax to the SUVmean of contralateral white matter were measured. For FLT PET, SUVmax and Patlak-derived metabolic flux parameter Kimax were measured for the same locus. A 5-point visual confidence scale was applied to FDG PET and FLT PET. Receiver operating curve analysis was applied to visual and quantitative results. Differences between recurrent tumor and radiation necrosis were tested by Kruskal-Wallis analysis. On the basis of follow-up Gd-enhanced MRI, lesion-specific recurrent tumor was defined as a definitive increase in size of the lesion, and radiation necrosis was defined as stability or regression. RESULTS: For FDG SUVmax, the FDG ratio of lesion-white matter, and FLT Kimax, there was a significant difference between mean values for recurrent tumor and radiation necrosis. Recurrent tumor was best identified by the FDG ratio of lesion-contralateral normal white matter (area under the curve of 0.98, confidence interval of 0.91 to 1.00, sensitivity of 100%, and specificity of 75% for an optimized cutoff value of 1.82). CONCLUSIONS: Both quantitative and visual determinations allow accurate differentiation between recurrent glioma and radiation necrosis by both FDG and FLT PET. In this small series, FLT PET offers no advantage over FDG PET.

Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.

UNLABELLED: The purpose of this study was to compare optimized whole-body (WB) and dedicated high-resolution contrast-enhanced PET/CT protocols and contrast enhanced CT in the preoperative staging of primary squamous cell carcinoma of the head and neck. METHODS: A total of 44 patients with clinically M0 squamous cell carcinoma of the head and neck underwent primary tumor resection and neck dissection within 6 wk of diagnostic imaging. Imaging consisted of a standard WB PET/CT protocol without intravenous contrast enhancement, followed by a high-resolution dedicated head and neck (HN) PET/CT protocol, which included diagnostic-quality contrast-enhanced CT (CECT). Imaging results were compared with histopathology. A 5-point scale was used to designate primary tumor localization and the presence of lymph node metastasis on a per-patient and per-level basis. For cervical nodes, receiver-operating-characteristic curves were generated to determine the differences in performance between the WB and HN PET/CT protocols and CECT. Sensitivity, specificity, positive and negative predictive values, and accuracy were calculated for primary tumor and cervical nodes. RESULTS: No statistical difference was observed between WB and HN PET/CT protocols, both of which significantly outperformed CECT, in the evaluation of the primary tumor. The performance of the HN PET/CT protocol was superior to that of the WB PET/CT in the detection of cervical node metastases, achieving statistical significance on a per-level basis and approaching significance on a per-patient basis, with the greatest advantage in the detection of small positive lymph nodes (<15 mm). No significant difference was observed between the WB PET/CT protocol and CECT in nodal staging, either on a per-patient or on a per-level basis. CONCLUSION: The primary advantage of the dedicated HN PET/CT protocol over the WB protocol or CECT in the staging of head and neck cancer is in the detection of small lymph node metastases.

Measurements of activation products associated with Havar foils from a GE PETtrace medical cyclotron using high resolution gamma spectroscopy.

Havar foils are specially engineered for beam-line windows used in the General Electric (GE) PETtrace medical cyclotron that can withstand the high pressure differentials and also temperatures developed near the target with proton bombardment. These foils effectively separate components along the beam line of the cyclotron. Various activation products are produced in the foils from the primary proton beam and other secondary radiations. An accurate estimate of the activation products is necessary for the disposal of these foils. The foils were assayed using two High Purity Germanium (HPGe) detectors calibrated over a wide energy range. These were positioned at different distances (0.10 m, 0.24 m, and 1.74 m) away from the detector faces to accommodate their high activities. A summary of the anticipated relative abundance of each activation product and a scatter plot of the average exposure rate per unit charge incident on the foil vs. time post-activation are provided. A detailed spectral analysis of the foils in the energy ranges between 12 keV to 300 keV and 12 keV through 2,500 keV revealed the residual activation products 56Co, 57Co, 58Co, 54Mn, and 183Re at 264 d post-irradiation. Spectral examinations of the different foils removed between 2003 and 2005 show the same activation products regardless of the irradiation time or foil position in the target assembly. The information presented in this paper can be used along with the integrated charge incident on the foils in estimating the activity of Havar foils for the purpose of disposal.

Estimating myocardial perfusion from dynamic contrast-enhanced CMR with a model-independent deconvolution method.

BACKGROUND: Model-independent analysis with B-spline regularization has been used to quantify myocardial blood flow (perfusion) in dynamic contrast-enhanced cardiovascular magnetic resonance (CMR) studies. However, the model-independent approach has not been extensively evaluated to determine how the contrast-to-noise ratio between blood and tissue enhancement affects estimates of myocardial perfusion and the degree to which the regularization is dependent on the noise in the measured enhancement data. We investigated these questions with a model-independent analysis method that uses iterative minimization and a temporal smoothness regularizer. Perfusion estimates using this method were compared to results from dynamic 13N-ammonia PET. RESULTS: An iterative model-independent analysis method was developed and tested to estimate regional and pixelwise myocardial perfusion in five normal subjects imaged with a saturation recovery turboFLASH sequence at 3 T CMR. Estimates of myocardial perfusion using model-independent analysis are dependent on the choice of the regularization weight parameter, which increases nonlinearly to handle large decreases in the contrast-to-noise ratio of the measured tissue enhancement data. Quantitative perfusion estimates in five subjects imaged with 3 T CMR were 1.1 +/- 0.8 ml/min/g at rest and 3.1 +/- 1.7 ml/min/g at adenosine stress. The perfusion estimates correlated with dynamic 13N-ammonia PET (y = 0.90x + 0.24, r = 0.85) and were similar to results from other validated CMR studies. CONCLUSION: This work shows that a model-independent analysis method that uses iterative minimization and temporal regularization can be used to quantify myocardial perfusion with dynamic contrast-enhanced perfusion CMR. Results from this method are robust to choices in the regularization weight parameter over relatively large ranges in the contrast-to-noise ratio of the tissue enhancement data.

Easy method of patient positioning for convergent-beam cardiac SPECT.

UNLABELLED: The use of convergent-beam SPECT can increase detection sensitivity; however, the projection data are likely to be truncated if the patient is not properly positioned. This article describes a patient-positioning method that has been adopted in our hospital for cardiac SPECT scans when convergent-beam collimators are used. METHODS: The system that we use has 3 detector heads and a patient table (i.e., bed) with 3 locking positions: left, center, and right. When convergent-beam collimators are used in a cardiac SPECT scan, the patient table is locked in the left position, and a noncircular contour orbit is set up. RESULTS: We were able to acquire truncation-free cardiac projections for all of our patients. CONCLUSION: Patient positioning in convergent-beam SPECT is important. If the patient is not positioned properly, then the heart may be truncated in some projection views. The use of the left locking position of the patient table positions the heart at the center of rotation, and the heart is not truncated in the projection data.

Position paper on the development of a middle level provider in nuclear medicine: the nuclear medicine practitioner.

The development of an educational program and credentialing structure to support and recognize an advanced level of the practice of nuclear medicine technology is now underway. This work parallels the efforts in many, if not most, health care disciplines as they seek to achieve the twin goals of developing enhanced career paths and providing the best possible patient care in an environment where science and technology can run roughshod over concepts taught in the classroom a mere decade ago. Education is key to both goals. A master's level degree in nuclear medicine technology, coupled with an advanced practice credential recognizing both the educational achievement and a level of clinical expertise, will give nuclear medicine practitioners the knowledge and the right to practice their profession at a high level of autonomy, leading to more efficient and higher quality health care services. To that end the following position paper was prepared by members of the Advance Practice Task Force of the SNMTS and presented to the SNMTS Executive Council and the SNM Board of Directors. In June 2005, the executive council and the board of directors approved a resolution supporting the establishment of a middle level provider in nuclear medicine known as the nuclear medicine practitioner.

Comparative evaluation of lesion detectability for 6 PET imaging platforms using a highly reproducible whole-body phantom with (22)Na lesions and localization ROC analysis.

UNLABELLED: The lesion detectability performance of 6 PET imaging platforms has been compared using a highly reproducible whole-body phantom and localization receiver operating characteristic (LROC) analysis. METHODS: A realistic whole-body phantom consisting of brain, thorax with lungs and liver, and pelvis with bladder was assembled and outfitted with 27 semipermanent (22)Na lesions of various sizes and activity concentrations. The background compartments were reproducibly filled with (18)F solutions. The phantom was imaged under the condition of equal emission scan time on 7 PET platforms: Advance, HR+, HR961, C-PET, IRIX, MCD, and AXIS. Imaging data were processed using manufacturer-supplied software and defaults, and LROC evaluation was performed using 11 human observers. RESULTS: Near-nominal counting rates were obtained for the NaI systems, and the bismuth germanate (BGO) systems were operated well below nominal counting rates. The BGO systems provided the highest lesion detection performance, followed by the large-area dedicated NaI system, and hybrid PET gamma cameras. Lesion detectability was highly dependent on lesion size, with all systems exhibiting similar performance for 16-mm lesions but differentiated performance for lesions < or =12 mm. CONCLUSION: Reconstruction methodology can have a significant effect on lesion detectability. PET lesion detectability performance is correlated with system cost and imaging characteristics. For a particular imaging task, care should be taken to ensure that the scanner being used is appropriate and that the scan time is adjusted accordingly to ensure good lesion detectability.

Comparison of Static and Dynamic Cardiac Perfusion Thallium-201 SPECT.

Cardiac SPECT is typically performed clinically with static imaging protocols and visually assessed for perfusion defects based upon the relative intensity of myocardial regions. Dynamic imaging, however, has the potential to provide quantitative measures of flow, possibly improving diagnosis. The objective of this study was to compare the information content of dynamic and static thallium SPECT imaging as measures of myocardial perfusion. Studies were performed in four canines, each with an occlusion placed on the left anterior descending coronary artery. Dynamic SPECT imaging was performed at rest and under adenosine stress, and subsets of the data were summed to provide corresponding static datasets for identical physiologic conditions. Microsphere-derived flow measurements were used as the gold standard. The dynamic data were fit to a two-compartment model to provide regional estimates of wash-in rate parameters. Occluded-to-normal ratios were also calculated for each canine study. The results show comparable correlations with microspheres for both wash-in and static scaled image intensities. The dynamic data provided higher defect contrasts, which were more accurate than the static occluded to normal ratios. Preliminary studies were also performed in two patients and the static and dynamic data compared. These results show that dynamic thallium imaging may provide improved diagnostic information compared to static imaging for myocardial perfusion SPECT studies.